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Although gold compounds are now recognized
as promising anticancer agents, so far only
gold(I) derivatives have been investigated for
this purpose, whereas the use of gold(III) com-
plexes has been hampered by their poor stabil-
ity under physiological conditions. We have
therefore carried out studies on selected gold-
(III) anticancer agents, showing enhanced sta-
bility due to the presence of chelating dithio-
carbamato ligands. We found that they induce
cancer cell death through both apoptotic and
nonapoptotic mechanisms. They also inhibit
thioredoxin reductase activity, generate free
radicals, modify some mitochondrial functions,
and increase ERK1/2 phosphorylation. Based on
our results, we propose and discuss a working
model suggesting that deregulation of the thiore-
doxin reductase/thioredoxin redox system is a
major mechanism involved in the anticancer ac-
tivity of the investigatedgold(III)-dithiocarbamato
complexes.
INTRODUCTION
The treatment of a variety of cancers by platinum deriva-
tives has encouraged the continuous investigation of al-
ternative metal-based drugs. Owing to their anti-inflam-
matory and immunosuppressive properties, some gold(I)
compounds used for the treatment of rheumatoid arthritis
[1–3] were considered for their possible anticancer activ-
ity. Indeed, some of the clinically established antiarthritic
gold(I) compounds, such as gold(I) thiomalate (myocrisin),
gold(I) thioglucose (solganol), and 2,3,4,6-tetra-o-acetyl-
1-thio-b-D-glucopyranosato-(S)-triethylphosphine gold(I)1128 Chemistry & Biology 14, 1128–1139, October 2007 ª2007(auranofin), were found to exert significant antitumor activ-
ity both in vitro and in vivo [4–10].
So far, while the potential anticancer action of gold(I) de-
rivatives has beenwidely investigated, the development of
gold(III) complexes as alternative antitumor agents has
been hampered by their poor stability under physiological
conditions. Although the stability of gold(III) metal center
may be enhanced by the coordination of multidentate li-
gands, the excess of stabilizationmay result in a loss of bi-
ological activity [11]. Nevertheless, recent studies showed
that some selected gold(III) complexes are able to exert
outstanding cytotoxic activity toward various tumor cell
lines with IC50 values falling in the range 1–10 mM [11–16].
In order to understand the mechanism of action of anti-
cancer agents, it is of paramount importance to identify
the molecular components involved in the cascade of
events that finally trigger cell death.
In light of the close chemical similarity between platinum
and gold compounds, it was believed that both might tar-
get DNA. However, in addition to a direct interaction with
DNA in vitro [17], both gold(I) and gold(III) complexes have
been reported to interact with other cellular components.
Recently, we have reported on the antiproliferative and
apoptotic activities of two gold(III)-methylsarcosinedithio-
carbamato derivatives toward a panel of human myeloid
leukemia cell lines. These novel gold(III) complexes ap-
pear to induce a strong downregulation of the antiapop-
totic Bcl-2 molecule and an upregulation of the proapop-
totic Bax protein, but only weak perturbations of the cell
cycle [18]. This behavior diverges from that of the classical
platinum(II) complexes which, instead, induce cell cycle
alterations resulting in an increase in G2M cell fraction
[19]. Furthermore, we have identified the proteasome as
a possible in vitro and in vivo target of gold(III)-dithiocarba-
mato derivatives such as complexes 1 and 4 (Figure 1A).
The inhibition of the proteasomal chymotrypsin-like activ-
ity results in the accumulation of ubiquinated proteins and
the proteasome target protein p27 in the highly metastatic
MDA-MB-231 human Caucasian breast adenocarcinomaElsevier Ltd All rights reserved
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Gold-Dithiocarbamato Complexes and Cancer CellsFigure 1. Chemical Drawings of the In-
vestigated Gold(III)-Dithiocarbamato
Complexes and Determination of the
Apoptotic Effects on HeLa Cells
(A) Investigated complexes: [Au(DMDT)Cl2]
(1), [Au(DMDT)Br2] (2), [Au(ESDT)Cl2] (3), [Au-
(ESDT)Br2] (4). Structure of the reference drug
cisplatin (cis-[PtCl2(NH3)2]) is also reported for
clarity.
(B) Phase-contrast microscopy representative
pictures of cell death after treatmentwith differ-
ent concentrations of complexes 2 (2.5/5/10/
15 mM) and 4 (5/10/20/30 mM), and cisplatin
(60 mM) for 24 h. Original magnification = 1003.
(C) Quantification of apoptosis through PARP
cleavage determination. After 24 hr treatment
the cells were collected, lysed, and aliquots of
total proteins subjected to western blot analy-
sis of PARP cleavage. Percentage of PARP
cleavage was calculated as the ratio between
densitometrical values of cleaved and un-
cleaved bands 3 100. Values are given as
means ± SE of at least three independent
experiments.cell line. In addition, treatment of MDA-MB-231 tumor-
bearing nude mice resulted in a significant inhibition of tu-
mor growth, associated to the inhibition of proteasome
activity and themassive induction of apoptosis in vivo [20].
On the other hand, recent data have identified mito-
chondria as suitable targets for gold complexes to exert
their cytotoxicity, as recently reviewed by McKeage
et al. [6]. In particular, mitochondrial thioredoxin reductase
appears to be a very specific target for gold(I) complexes,
such as auranofin, aurothiomalate, and other gold(I)-trie-
thylphosphine derivatives [21], and gold(III) complexes
containing diethylendiamino-substituted pyridino and bi-
pyridino ligands [22, 23]. This finding is highly significant
as mitochondria are now taken into account as potential
targets for chemotherapeutic drugs due to their well-
known key role in apoptosis.
As a natural continuation of our previous studies,we here
report on the effect of some recently synthesized gold(III)-
dithiocarbamato derivatives, namely [Au(DMDT)X2] and
[Au(ESDT)X2] (DMDT = N,N-dimethyldithiocarbamato;
ESDT = ethylsarcosinedithiocarbamato; X = Cl, Br)
(Figure 1A) [15], on cell cytotoxicity and mitochondrial
functions. Analyses were carried out at molecular, subcel-
lular, and cellular levels. We found that they trigger cell
death by activating both apoptotic and nonapoptotic
pathways. They alter some mitochondrial functions suchChemistry & Biology 14, 1128–11as membrane potential and permeability conditions, stim-
ulate ROS generation, and are particularly effective in in-
hibiting the activity of selenoenzyme thioredoxin reductase
with similar or even higher efficiency compared to other
gold(III) complexes [22, 24]. Intriguingly, we have evidence
that treatment of HeLa cells with these gold(III)-dithiocar-
bamato complexes induces phosphorylation of ERK, and
that ERK activation can be completely blocked by the an-
tioxidant N-acetyl-L-cysteine (NAC), whereas treatment
with Trolox is ineffective. Based on our findings, we pro-
pose and discuss a workingmodel of the molecular mech-
anisms involved in the cell death induced by the investi-
gated gold(III) anticancer agents.
RESULTS
X-Ray Crystallography
The complexes [Au(DMDT)X2] [X = Cl (1), Br (2)] and
[Au(ESDT)X2] [X = Cl (3), Br (4)] (Figure 1A) have been de-
signed to reproduce very closely the main features of cis-
platin. Conclusions reached upon application of several
spectroscopic techniques suggest that coordination of
both DMDT and ESDT ligands takes place in a near
square-planar geometry through the sulfur-donating
atoms, with the NCSS moiety coordinating the metal
center in a bidentate symmetrical mode. The remaining39, October 2007 ª2007 Elsevier Ltd All rights reserved 1129
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Gold-Dithiocarbamato Complexes and Cancer Cellscoordination positions are occupied by two cis-gold(III)-
halogen atoms that may undergo hydrolysis [15]. This
structural hypothesis is also supported by density func-
tional calculations previously carried out for some analo-
gous gold(III)-dithiocarbamato complexes [25]. In addi-
tion, we recently determined the X-ray structure of
complex 4, which is in agreement with the previously re-
ported spectroscopic data (see the Supplemental Data
available with this article online).
Apoptotic Activity
The apoptotic activity of complexes 1–4was evaluated on
human cervical carcinoma HeLa cells incubated for 24 h
with increasing drug concentrations. Concentrations
ranged from 2.5 to 15 mM and from 5 to 30 mM for
DMDT (1 and 2) and ESDT (3 and 4) derivatives, respec-
tively, with their IC50 values (concentration of drug result-
ing in 50% inhibition of cell growth) being slightly different
toward the same human tumor cell lines [15, 16]. Cisplatin
was also tested as a reference drug. Analysis of cultures
after the treatment showed that both DMDT and ESDT
gold(III) derivatives were able to induce cell death in
a dose-dependent way (Figure 1B); no substantial differ-
ences were observed among chloro- and bromo-
derivatives containing the same dithiocarbamato ligand.
To determine whether the observed cell death was due
to the activation of an apoptotic pathway, we analyzed the
poly-(ADP-ribose)-polymerase (PARP) cleavage. PARP is
a nuclear enzyme, activated by DNA damage, involved in
DNA repair, cell death, and inflammation [26]. Moreover,
PARP is a specific substrate for caspases 3 and 7; there-
fore, PARP cleavage is generally accepted as a marker for
apoptosis [27]. Indeed, apoptosis is a form of cell death
characterized by the activation of caspases (cysteinyl as-
partate specific protease) that cleave multiple targets in
the cell. Thus, after microscope observation, the cells
were collected, lysed, and total proteins subjected to
western blot analysis. As shown in Figure 1C, the percent-
age of PARP cleavage after 24 hr treatment, quantified by
densitometric analysis, was nearly the same for all tested
gold(III) complexes and, surprisingly, non-dose-depen-
dent (except for lower dose treatments). These findings
contrast with those obtained from the morphological ex-
amination of the cultures, in which the cell death appeared
to be dose-dependent (Figure 1B). Thus, it is likely that our
compounds may trigger cell death by activating not only
apoptotic pathways but also other death mechanisms
(i.e., necrosis). On the contrary, cells treated with cisplatin
induced a complete PARP cleavage, confirming that the
reference drug leads to cell death only through an apopto-
tic pathway.
Effects on Mitochondrial Functions
Although mitochondria have long been considered to be
solely a powerhouse for production of cellular energy, re-
cently they have been clearly recognized to play a critical
role in the apoptotic process [28]. Therefore, the physio-
logical consequences on the mitochondrial respiratory
parameters, membrane potential, and permeability transi-1130 Chemistry & Biology 14, 1128–1139, October 2007 ª2007tion conditions after treatment with complexes 1–4 were
studied. As summarized in Figure 2A, the respiratory con-
trol ratio (RCR) measured in whole mitochondria is
scarcely affected, and uncoupled respiration shows a
limited inhibition (data not shown), thus indicating that
the electron flow along the respiratory chain is not signifi-
cantly affected. In agreement with these observations, in
Figure 2. Oxygen Uptake by Rat Liver Mitochondria and Sub-
mitochondrial Particles
Rat liver mitochondria (A) or submitochondrial particles (B and C) were
incubated at 25C with complexes 1–4 to a final concentration of 5 mM
for mitochondria and 10 mM for submitochondrial particles in the suit-
able medium (see Experimental Procedures). For submitochondrial
particles either succinate (B) or NADH (C) were used as substrates. Ox-
ygen consumption wasmeasured as reported in the Experimental Pro-
cedures section. Respiration control ratio (RCR) was calculated as res-
piration rate in state 3/respiration rate in state 4. Values are given as
means ± SE of at least three independent experiments.Elsevier Ltd All rights reserved
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Gold-Dithiocarbamato Complexes and Cancer CellsFigure 3. Effect on Mitochondrial Mem-
brane Potential and Swelling
(A) Mitochondrial membrane potential was
estimated as reported in the Experimental Pro-
cedures. Mitochondria were energized by the
addition of 5mMsuccinate (arrow). Concentra-
tion of gold(III) complexes was: 0 (a), 1 mM (b),
2 mM (c), 3 mM (d), 5 mM (e). Values are reported
as relative fluorescence units.
(B) Induction of mitochondrial swelling was es-
timated as described in the Experimental Pro-
cedures with complexes 1–4 to a final concen-
tration of 2 mM.submitochondrial particles the respiration is modified by
approximately 10%–20% after treatment with the various
gold(III) complexes [using either succinate (Figure 2B) or
reduced nicotinamide adenine dinucleotide (NADH,
Figure 2C) as substrates]. Similarly to the observed apo-
ptotic effect toward HeLa cells (see above), negligible dif-
ferences were detected among chloro- and bromo-deriv-
atives containing the same dithiocarbamato ligand.
Interestingly, different results were obtained when the
membrane potential was estimated (Figure 3A). In fact,
whereas complexes 1 and 2 caused a marked drop of
membrane potential after about 20 to 30 min have
elapsed, complex 4 was able to depolarize membrane
after about 32 min of incubation, and complex 3 showed
an intermediate behavior. In addition, all the investigated
gold(III)-dithiocarbamato derivatives exhibit a marked ef-
fect when permeability transition, measured in terms of
mitochondrial swelling, was taken into account. As re-
ported in Figure 3B, a large swelling is apparent after incu-
bation with complexes 1–4; nevertheless, it is worth noting
that swelling is faster in the presence of the two DMDT de-
rivatives (1 and 2), whereas a longer lag occurs in the caseChemistry & Biology 14, 1128–1of ESDT derivatives (3 and 4), which take a longer time to
accomplish the swelling. As well as the swelling induced
by auranofin [21], also in this case swelling is dependent
on the presence of a low concentration of calcium ions
as observed by the inhibitory effect elicited by calcium
chelators (EGTA) or inhibitors of mitochondrial calcium
uptake such as ruthenium red (data not shown).
Estimation of ROS Accumulation in Isolated
Mitochondria and HeLa Cells
The effect of complexes 1–4 on the production of reactive
oxygen species (ROS), in particular hydrogen peroxide, in
isolated rat liver mitochondria is shown in Figures 4A and
4B. As apparent, the addition of any of the complexes 1–4
strongly stimulates the formation of hydrogen peroxide,
detected by means of Amplex Red/HRP (10 acetyl-3,7-
dihydroxyphenoxazine/horseradish peroxidase) assay.
The formation of hydrogen peroxide is further increased
when antimycin is added (Figure 4A). By inhibiting the mi-
tochondrial complex III, antimycin favors the production
of superoxide anion which, after dismutation, is converted
to hydrogen peroxide. Analogously, when antimycin is139, October 2007 ª2007 Elsevier Ltd All rights reserved 1131
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Gold-Dithiocarbamato Complexes and Cancer CellsFigure 4. Evolution of Hydrogen Perox-
ide in Isolated Rat Liver Mitochondria
and in Cultured HeLa Cells
Hydrogen peroxide formed by exposure of iso-
lated rat liver mitochondria to complexes 1–4.
The fluorogenic probe Amplex Red and HRP
were used at concentration of 10 mM and 0.1
units/ml, respectively. The extent of hydrogen
peroxide evolution was reported as relative
fluorescence units. Antimycin (1 mM) was
added after (A) or before (B) the various gold(III)
complexes (1 mM). (C) ROS formation in HeLa
cells was determined using the oxidation-sen-
sitive probe DHR-123. Cells were loaded with
DHR-123 (5 mM) for 30 min, and then exposed
to complexes 2 and 4 (10 mM) for an additional
30 min. For comparison purposes, cisplatin
(60 mM)was tested under the same experimen-
tal conditions. ROS generation was examined
using a Zeiss LSM-510 confocal laser micro-
scope equipped with a CO2- and tempera-
ture-controlled chamber.added before incubating mitochondria with any of the in-
vestigated gold(III) complexes (Figure 4B), again they fur-
ther stimulate the formation of hydrogen peroxide. The
effectiveness of the four complexes is rather similar, al-
though the two DMDT derivatives seem to be slightly
more efficient than the ESDT counterparts.
As experiments carried out in isolated rat livermitochon-
dria showed that complexes 1–4 are able to induce forma-
tion of hydrogen peroxide, we checked whether these
complexes trigger ROS generation also in HeLa cells.
Intracellular ROS were detected using the oxidation-
sensitive probe dihydrorhodamine-123 (DHR-123), which
is reported to react preferentially with hydrogen peroxide
and to localize at themitochondrial level. Results, reported
in Figure 4C, showed that the treatment with complexes
2 and 4 increases the oxidized state of the cells, detected
as enhancement of fluorescence intensity of the probe;
similar results were obtained with complexes 1 and 3
(data not shown). Conversely, control nontreated cells or
cells treatedwith cisplatin showed only aweak fluorescent
background, most likely due to small DHR-123 oxidation
occurring during its manipulation. Thus, these results
indicate that our gold(III) complexes are able to induce
ROS in both isolated mitochondria and cells.
Effect of the Antioxidants Trolox and NAC on ROS
Production and PARP Cleavage in HeLa Cells
To investigate whether ROS were responsible for the ob-
served cell death, HeLa cells were treated in the presence
of either NAC or the hydrophilic form of vitamin E (Trolox,
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid).
Both are good ROS scavengers. NAC is a reducing thiol
that helps to maintain the cellular thiol redox balance,
whereas Trolox interacts preferentially with free radicals
such as the peroxyl radicals. Given that all four complexes
exhibited similar apoptotic and oxidative behavior, com-
plex 4 was chosen as representative. Using DHR-123 as
a probe for ROS detection, we found that when NAC
(1 mM) or Trolox (100 mM) were added to cultures before1132 Chemistry & Biology 14, 1128–1139, October 2007 ª2007adding complex 4, the oxidation state of the probe was re-
duced to levels comparable to those of nontreated control
cells (Figure 5A). However, when we analyzed the survival
of cells cotreated with NAC or Trolox and complex 4, we
found that while NAC treatment was able to prevent cell
death and PARP cleavage, Trolox was not (Figures 5B
and 5C). Indeed, the cells exhibited comparable mortality
and PARP cleavage regardless of Trolox presence (Fig-
ures 5B–5D). These apparently contradictory data sug-
gest that caspase activation, that ultimately causes
PARP cleavage, is not directly triggered by ROS, and indi-
cate that gold(III) compounds might promote cell death by
other mechanisms that are counteracted by NAC.
Molecular Targets at Mitochondrial
and Cytosolic Levels
Thioredoxin reductase (TrxR) appears to be a very specific
intracellular target for antitumor agents. In particular, the
mitochondrial isoform may be of potential interest regard-
ing the role of these organelles in the apoptotic process,
and previous reports indicate that both gold(I) and gold(III)
complexes are highly specific inhibitors of mitochondrial
thioredoxin reductase [22]. Thioredoxin reductase is a se-
lenoenzyme with a selenol group in the active site at the C
terminus of the enzyme [29]. Gold compounds preferen-
tially interact with this site since selenol displays a greater
affinity toward heavy metals [30].
On the basis of these considerations, our gold(III)-di-
thiocarbamato derivatives were tested to study their po-
tential inhibitory effect on this selenoenzyme. The inhibi-
tory activity of complexes 1–4 on both cytosolic (TrxR1)
and mitochondrial (TrxR2) thioredoxin reductase is re-
ported in Figure 6. The cytosolic isoform (Figure 6A) is
particularly sensitive to the action of gold(III) compounds,
all of them being inhibitory agents at nanomolar level, ex-
hibiting IC50 values ranging from 5.67 nM (complex 1) to
17.01 nM (complex 3).Mitochondrial thioredoxin reductase
(Figure 6B) seems to be less sensitive to the treatment,
with IC50 values ranging from 24.74 nM (complex 1) toElsevier Ltd All rights reserved
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Gold-Dithiocarbamato Complexes and Cancer CellsFigure 5. Effect of Treatment with the
Antioxidants Trolox and NAC on ROS
Generation in Cell Death
(A) HeLa cells were treated and examined for
ROS generation as described in Figure 4C.
Graphs report the profile of DHR-123 relative
intensity quantified using the Zeiss Profile soft-
ware. Profiles are referred to the signals along
a line traced across few cells. When present,
Trolox (100 mM) or NAC (1 mM) were added
for 1 h and 18 h, respectively, before treatment
with both DHR-123 and complex 4 (10 mM).
(B) Phase-contrast microscopy representative
pictures showing HeLa cells pretreated for
1 h with Trolox (100 mM) or 18 h with NAC
(1 mM) and then incubated for additional 24 h
in medium containing 10 mM complex 4. Origi-
nal magnification = 1003. Quantification of ap-
optosis through PARP cleavage determination.
(C) PARP cleavage was analyzed by western
blot as described in the Experimental Proce-
dures.
(D) Graph showing the percentage of PARP
cleavage calculated as the ratio between den-
sitometrical values of cleaved and uncleaved
bands 3 100. Values are given as means ±
SE of at least three independent experiments.35.87 nM (complex 4). However, in both cases the inhibi-
tory effect is massive, and it is likely to be due to the inter-
action with the selenol residue present in the active site of
thioredoxin reductase. In fact, thioredoxin reductase ob-
tained from E. coli, lacking the cysteine/selenocysteine
motif at the C terminus, is almost totally insensitive to
the gold(III) complexes (Figure 6C). Glutathione reductase
is also unaffected by the treatment with complexes 1–4,
and this is in agreement with the fact that, although gluta-
thione reductase is a protein structurally and functionally
close to thioredoxin reductase and belongs to the same
family of the pyridine nucleotide oxidoreductase, it lacks
selenol at the catalytic site (Figure 6D). In fact, as previ-
ously reported, it requires much greater concentrations
of auranofinandothergold compounds tobe inhibited [31].
Analysis of ERK Phosphorylation
Mammalian thioredoxin reductase is a key enzyme for
maintenance of intracellular reduced environment since
it acts as a direct antioxidant of thioredoxin (Trx). Impair-
ment of TrxR will lead to increased levels of oxidized
Trx. Trx protects cells from a variety of oxidative stresses
by regulating the redox state and activity of many cellular
proteins that control cell growth. In the reduced form, Trx
associates with apoptosis signal-regulating kinase-1/
mitogen-activated protein kinase kinase kinase (ASK-
1/MAPKKK). Oxidation of Trx results in its dissociation
and consequent activation of the MAPK pathway [32].
Recent studies suggest that apoptotic stimuli are trans-
mitted to caspases through the activation of MAPKKK
[33], and it is also believed that, depending on the length
of MAPKs activation (e.g., transient or prolonged), they
might trigger cell proliferation or death [34]. Furthermore,
it was shown that ROS, in particular hydrogen peroxide,Chemistry & Biology 14, 1128–1might lead to the activation of extracellular signal-regu-
lated kinases (ERKs) [35].
In order to investigate the influence of our gold(III) com-
plexes on MAPK signaling, we examined the activation of
ERK1 (p44) and ERK2 (p42). Kinetic studies showed that
treatment with complex 4 rapidly increases phospho-
ERK levels (Figure 6E). Nevertheless, when cells were
treated in the presence of Trolox, no significant increase
in ERK phosphorylation was observed (Figure 6F). These
results might indicate that hydrogen peroxide accumula-
tion influences MAPK signaling. Since the antioxidants
Trolox and NAC showed different effects on cell survival
and PARP cleavage in long-term treatment (Figures 5B–
5D), we also studied the ERK phosphorylation state in
cells treated with complex 4 for 24 hr in the presence or
absence of either Trolox or NAC. We found that Trolox
was not able to block the increase of phospho-ERK
(Figure 6G); on the contrary, NAC treatment completely
blocked the induction of phospho-ERK by complex 4
(Figure 6H). These data may explain the different behavior
of the two antioxidants on cell survival. It is worth noting
that NAC, even at relatively high concentration, does not
alter the inhibitory effect of gold(III)-dithiocarbamato com-
plexes on thioredoxin reductase.
DISCUSSION
The here investigated gold(III) complexes 1–4 were re-
cently proved to be 1- to 4-fold more cytotoxic in vitro
than cisplatin, even toward human tumor cell lines intrinsi-
cally resistant to cisplatin itself [15]. Moreover, they ap-
peared to induce cell death also on cisplatin-resistant
cell lines, with activity levels comparable to those on the
corresponding cisplatin-sensitive cell lines, ruling out the139, October 2007 ª2007 Elsevier Ltd All rights reserved 1133
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Gold-Dithiocarbamato Complexes and Cancer CellsFigure 6. Effect on Thioredoxin and Glu-
tathione Reductase and Induction of
ERK Phosphorylation
Cytosolic (A), mitochondrial (B) and E. coli (C)
thioredoxin reductases and glutathione reduc-
tase (D) were incubated as described in the
Experimental Procedures. Gold(III) complexes
were added at the indicated concentrations.
The final concentrations of the enzymes were
2.1 and 3.8 nM for TrxR1 and TrxR2, respec-
tively. E. coli thioredoxin reductasewas 40.2 mg/
ml while glutathione reductase was 4.3 nM. The
inhibitory effect of each tested compound was
evaluated in comparisonwith the corresponding
control (untreated thioredoxin and glutathione
reductase). Dose-response curves were calcu-
lated over the indicated rangeof concentrations,
enabling IC50 values to be obtained. Values are
given as means ± SE of at least three indepen-
dent experiments. HeLa cells (1.5 3 105 cells
per well) were incubated with complex 4
(10 mM) for 30 min to 3 h in the presence (F) or
not (E) of 100 mM Trolox or for 24 h with 100 mM
Trolox (G) or 1 mM NAC (H). At the end of treat-
ments, aliquots of protein lysate, corresponding
to 4.53 104 cells, were subjected to SDS-PAGE
in 10% gel. Proteins were then transferred to
PVDF and immunodecorated using anti-ERK
and anti-phospho-ERK antibodies. Blots are
representative of at least two independent ex-
periments.occurrence of crossresistance phenomena and support-
ing the hypothesis of a different mechanism of action
[15]. The chemical characterization carried out in aqueous
solution allowed us to establish that they are reasonably
stable within a physiologically relevant environment, an
essential prerequisite for any further pharmacological
evaluation [16]. Moreover, they show high reactivity to-
ward some biologically relevant isolatedmacromolecules,
and dramatically inhibit both DNA and RNA synthesis, and
induce DNA lesions with a faster kinetics than cisplatin.
Nevertheless, they also induce a strong and fast hemolytic
effect (compared to cisplatin), suggesting that intracellular
DNAmight not represent their primary or exclusive biolog-
ical target [16]. These encouraging results prompted us to
carry out further investigations aimed at elucidating their
mechanism of action.
Although gold drugs have been in clinical use for over 70
years, their exact mechanism of action is on debate, as
their specific cellular targets are still unclear. Recent
studies showed that mitochondria may play a major role1134 Chemistry & Biology 14, 1128–1139, October 2007 ª2007in their mechanism of cytotoxicity and antitumor activity
[6]. Gold(III) complexes were generally proved to be less
effective than gold(I) derivatives, such as auranofin, in
stimulating mitochondrial swelling, and this might depend
on the different permeability characteristics of these com-
plexes [22]. Moreover, the production of hydrogen perox-
ide by gold(I) compounds was already observed with aur-
anofin both in isolated mitochondria and in cellular
systems [36]. We demonstrate that also gold(III) dithiocar-
bamato derivatives are able to spark the production of this
reactive oxygen species. Furthermore, due to the lack of
effect of these complexes on respiration it is reasonable
to conclude that the observed increase in hydrogen per-
oxide is essentially due to their inhibitory effect on thiore-
doxin reductase rather than to stimulation of the mito-
chondrial electron transport chain.
Besides the strong impairment on thioredoxin reduc-
tase, we found that gold(III)-dithiocarbamato complexes
increase the levels of phosphorylated ERK1/2 in HeLa
cells. Activation of the ERK1/2 pathway by reactiveElsevier Ltd All rights reserved
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Gold-Dithiocarbamato Complexes and Cancer CellsFigure 7. Proposed Model of the Molecular Mechanisms Underlying Gold(III)-Dithiocarbamato Derivatives-Induced Cell Deathoxygen species has been reported by several groups [37–
39]. Nevertheless, more recently it has been reported that
ERK1/2 play a crucial role in the signaling downstream
ASK1. Indeed, apoptosis induced by the iron chelator de-
feroxamine [40] or acrolein [41] is mediated by both p38
and ERK activation in keratinocytes. Interestingly, acrolein
is a potent inhibitor of thioredoxin reductase [42]. More-
over, it was shown that in cultured cerebellar granule
neurons in low potassium-induced apoptosis the ERK
phosphorylation was activated by the ASK1-p38MAPK
pathway [43]. Activation of MAP kinases as a mechanism
of apoptosis induced by gold(I) compounds was also sug-
gested by Park and coworkers [33]. However, they re-
ported that in promyelocytic leukemia HL60 cells treated
with auranofin the major kinase involved was p38-
MAPK, whereas activation of ERK was independent of
auranofin concentration. These data, apparently in con-
flict with our findings, also indicate a direct involvement
of ASK1 in gold compounds-induced cell death. The acti-
vation of different effector kinases downstream of ASK1
might be explained as the results of the different cell sys-
tem used and the experimental timing.
The fact that incubation with the scavenger Trolox can
reduce phospho-ERK levels after short-term treatment
(3 h) with the investigated gold(III) complexes but it is un-
able to block ERK activation, as well as cell toxicity and
PARP cleavage, when the treatment is prolonged for 24
h, suggests that our compounds trigger ERK phosphory-
lation mainly through ASK1 pathway deregulation. This
hypothesis is supported by the results obtained by using
NAC as an alternative antioxidant, and the reported capa-Chemistry & Biology 14, 1128–11bility of NAC itself to prevent dissociation of the Trx-ASK
complex [44], most likely by maintaining thioredoxin re-
duced. In addition, these data strongly indicate that sus-
tained and long-lasting stimulation of ERK phosphoryla-
tion is directly involved in cell death. Indeed, several
groups reported that ERK1/2 play important roles not
only in cell proliferation and survival, but also in the pro-
gression of apoptosis [45, 46]. The mechanisms by which
ERK induces apoptosis are not completely clarified yet,
but it is believed that might occur at many different levels
involving both the extrinsic and intrinsic apoptotic path-
ways [45]. For instance, inhibition of ERK phosphorylation
decreases Bax expression [39] and, in addition, ERK1/2
activity is downregulated by the ubiquitin/proteasome
system [47]. These results rationalize recent observations
obtained with gold(III)-methylsarcosinedithiocarbamato
complexes indicating that they both upregulate Bax and
downregulate Bcl2 [18], whereas complex 1 exerts an in-
hibitory action on the proteasome system [20]. Hence,
proteasome inhibition can also explain the observed
long-lasting persistence of phosphorylated ERK1/2.
Based on these results, we propose a workingmodel for
the mechanism of action of our gold(III)-dithiocarbamato
complexes (Figure 7). As already reported for some orga-
nogold(III) compounds [24], complexes 1–4 can inhibit thi-
oredoxin reductase by irreversible covalent binding to its
catalytic site. This hampers the function of both mitochon-
drial andcytosolic thioredoxin reductases that act asmedi-
ators of electron flow from NADPH to peroxiredoxins
through Trx, and lead to an increase in the oxidized form
of Trx and to the accumulation of hydrogen peroxide.39, October 2007 ª2007 Elsevier Ltd All rights reserved 1135
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Indeed, it has been reported that hydrogen peroxide accu-
mulation can trigger ERK1/2 phosphorylation [48]. On the
other hand, oxidation of Trx will bring on dissociation of the
complex Trx-ASK1 and activation of MAPK system ob-
served as subsequent ERK1/2 phosphorylation [49]. Thus,
wehypothesize thatapersistentERK1/2activation triggered
at first by accumulation of hydrogen peroxide and then by
activation of ASK-1 may be responsible for cell death.
SIGNIFICANCE
Gold compounds possess a variety of therapeutic po-
tentials ranging fromattenuationof inflammation, sup-
pression of autoimmunity, and promising antitumor
activity. Due to their chemical similarity to platinum(II)
compounds, it was believed that gold(III) compounds
might have DNA as their biological target. However,
gold(III) complexes have been reported to interact
alsowithseveralothercellular components,andrecent
data indicated mitochondria as potential targets. Nev-
ertheless, so far the mechanism of action of gold(III)
compounds is unclear and there is little understanding
of how they can elicit their activity.
By means of cellular, biochemical, and molecular
approaches, we analyzed the mechanism of action of
recently synthesized gold(III)-dithiocarbamato deriva-
tives. These compounds are able to trigger cell death,
to induce ROS generation, to modify some mitochon-
drial functions, and to inactivate both cytosolic and
mitochondrial thioredoxin reductases. Besides the
impairment of TrxR, they induce elevated and long-
lasting levels of phosphorylated ERK1/2; persistent
high levels of phosphorylated ERKmight be the cause
of cell death. Thus, it is worthwhile to envisage that
gold(III) complexes favor the dissociation of the Trx-
ASK complex and the consequent prolonged activa-
tion of MAPKinase pathways by inhibiting the TrxR/
Trx redox system. This hypothesis is further supported
by the finding that both ERK phosphorylation and cell
death were inhibited by treatment with the antioxidant
NAC, whereas the peroxyl scavenger Trolox was inef-
fective. Indeed, it has been reported that NAC itself
prevents the dissociation of the complex Trx/ASK
kinase,most likely by keeping Trx in the reduced state.
Drugs that target specifically TrxR are of undoubted
therapeutic relevance given that many tumors exhibit
increased levels of TrxR or Trx, whichmight contribute
to resistance of cancer to therapy by scavenging ROS
eventually generated by various anticancer agents.
EXPERIMENTAL PROCEDURES
Materials
Human cervical carcinoma HeLa cell line was obtained from the
American Type Culture Collection. Cisplatin (Bristol-Myers Squibb),
Dulbecco’s modified Eagle medium (DMEM, Sigma Aldrich), fetal bo-
vine serum (FBS, GIBCO), L-glutamine (GIBCO), penicillin (Pharmacia),
streptomycin (Bristol-Myers Squibb), phosphate buffered saline solu-
tion (PBS,Sigma), low fatmilk (Roche), rotenone,oligomycin,antimycin,1136 Chemistry & Biology 14, 1128–1139, October 2007 ª2007carbonylcyanide m-chlorophenylhydrazone (CCCP), horseradish per-
oxidase (HRP), N-acetyl-L-cysteine (NAC), 5,50-dithiobis-(2-nitroben-
zoic acid) (DTNB) and Rhodamine-123 were purchased from Sigma.
6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox)
was purchased from Fluka. Dihydrorhodamine-123 (DHR-123) and
10-acetyl-3,7-dihydroxyphenoxazine (Amplex Red) were purchased
from Invitrogen-Molecular Probes. All reagents and solvents were of
highpurity andwere usedas purchasedwithout any further purification.
Gold(III) complexes 1–4 were synthesized as previously described
[15]. Before use, gold(III) complexes were dissolved in DMSO just be-
fore the experiments; calculated amounts of drug solutions were then
added to the proper medium, to a final organic solvent concentration
lower than 0.5% (v/v). All the tested complexes were proved, by 1H
NMR studies, to be stable in DMSO over 48 h [15].
X-Ray Crystallography
Crystals of complex 4 suitable for X-ray crystal-structure determina-
tion were obtained from an acetone/hexane (1:1) solution at 4C. Dif-
fraction data were collected using a Bruker Smart Apex CCD diffrac-
tometer equipped with an Oxford Cryosystems low-temperature
device operating at 150 K. The diffraction pattern was indexed with
two orientation matrices related via a 2-fold ration about the [100] di-
rection (CELL NOW [50]). Reflections from both domains were inte-
grated simultaneously and used in refinement (SAINT [51]). An absorp-
tion correction was performedwith themultiscan procedure TWINABS
[52]. The structure was solved by Pattersonmethods (DIRDIF) [53], and
refined against F2 using SHELXL-97 [54]. H atoms were placed in cal-
culated positions. The terminal EtO– group is disordered over two ori-
entations to avoid a close contact across an inversion center. The oc-
cupancies were fixed at 0.5, and similarity restraints were applied to
the bond distances and angles in the part-weight fragments. The
twin scale factor refined to 0.523(15). X-ray crystallographic data are
available in the Supplemental Data. The crystal structure of complex
4 has been deposited at the Cambridge Crystallographic Data Centre
and allocated the deposition number CCDC641437. These data can
be obtained free of charge from The Cambridge Crystallographic
Data Centre via http://www.ccdc.cam.ac.uk/data_request/cif.
Determination of Apoptotic Activity in HeLa Cells
HeLa cells were cultured at 37C in 5%CO2 atmosphere in Dulbecco’s
modified Eagle medium supplemented with 10% fetal bovine serum, 2
mM L-glutamine and antibiotics (200 units/ml penicillin, 150 units/ml
streptomycin). For apoptosis analysis, cells were seeded into 6-well
plates at a density of 1.53 105 cells per well, and exposed to the gold-
(III) complexes or cisplatin. After 24 h of incubation, cell death was
evaluated by visual inspection using an Olympus phase-contrast mi-
croscope. After microscope observation, cells were collected and
subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
and western blot analysis (see below).
SDS-PAGE and Western Blot Analysis
After treatment, all cells, including floating dead ones, were collected,
and total proteins were extracted in Laemmli buffer (LB-1X: 50 mM
Tris-HCl [pH 6.8], 2% SDS, 10% glycerol, 1% b-mercaptoethanol,
0.05% bromophenol blue) supplemented with a cocktail of protease
inhibitors (Roche) and 50 mM sodium fluoride. Aliquots of lysate
were subjected to SDS-PAGE. Proteins were then transferred to poly-
vinylidene fluoride (PVDF) membranes (Amersham) and probed with
the specific antibodies. The following antibodies were utilized: rabbit
polyclonal anti-PARP, mouse monoclonal anti-phospho-ERK1/2, and
rabbit polyclonal anti-total ERK1/2 (Cell Signaling Technology) at the
manufacturer’s indicated concentrations. Secondary HRP-conjugated
antibodies (sheep anti-mouse or donkey anti-rabbit, Amersham) were
used at a concentration of 1:10,000 in PBS-milk (5% powdered
skimmedmilk in PBSwith 0.05%Tween). Membraneswere developed
using the enhanced chemiluminescence detection system ECL-Plus
(Amersham). Densitometric analysis was carried out using the Multia-
nalyst Biorad analysis software.Elsevier Ltd All rights reserved
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and Submitochondrial Particles
Mitochondria were prepared from rat liver by differential centrifugation
essentially according to Myers et al. [55] in a medium containing 220
mM mannitol, 70 mM sucrose, 1 mM EDTA and 5 mM HEPES (pH
7.0). EDTA was omitted in the final washing and in the mitochondrial
suspension. Mitochondrial proteins were estimated with the biuret
procedure using BSA as standard [56].
To obtain submitochondrial particles, mitochondria were diluted to
about 20 mg/ml with 25 mM Tris-HCl buffer (pH 8.0) and sonicated
twice for 30 s. The suspension was then centrifuged at 10,000 x g
for 10 min to remove the unbroken mitochondria, the pellet was dis-
carded, and the supernatant again centrifuged at 105,000 x g for 30
min. The obtained pellet, after washing, was suspended in a small vol-
ume of the same medium used for mitochondria.
Measurement of Oxygen Uptake
Rat liver mitochondria (1 mg/ml) or submitochondrial particles (0.5 mg/
ml) were treated with complexes 1–4 at 25C in 0.1 M sucrose, 50 mM
KCl, 1 mMMgCl2, 1 mM NaH2PO4, 20 mM HEPES/Tris-HCl buffer (pH
7.4), 1 mM EGTA, and 5 mM glutamate plus 5 mM malate as sub-
strates. State 3 respiration was initiated by adding 0.3 mM ADP. For
submitochondrial particles either 7.5 mM succinate or 0.75 mM
NADH were used as substrate. Oxygen uptake was estimated polaro-
graphically at 25C using a Clark-type oxygen electrode (Yellow
Springs) [57] fitted in a water-jacketed chamber with continuous stir-
ring. Mitochondria with respiratory control ratio of 4 or greater were uti-
lized. To validate the oxygen uptake experiments, positive controls
were run in the presence of 0.5 mMCCCP to obtain the maximal respi-
ration and 1 mM antimycin A to completely inhibit oxygen consumption
(not shown).
Measurement of Membrane Potential
Mitochondrial membrane potential was estimated by means of the
fluorescent dye rhodamine-123 according to Emaus et al. [58]. Mito-
chondrial proteins (0.3 mg/ml) were incubated at 25C in 100 mM su-
crose, 50 mM KCl, 20 mM HEPES/Tris-HCl buffer (pH 7.4), 1 mM
NaH2PO4, 1 mM MgCl2, 6 mM rotenone, and 0.3 mM rhodamine-123.
Complexes 1–4 were then added at increasing concentrations. Fluo-
rescencewas estimated in amicroplate reader (Ascent FL, Labsystem)
at 485 nm (excitationwavelength) and 527 nm (emission wavelength) in
a final volume of 250 ml. To validate the estimation, a positive control
with the uncoupler CCCP (0.5 mM) showing a rapid and complete col-
lapse of membrane potential was performed (not shown).
Estimation of Mitochondrial Swelling
Rat liver mitochondria (0.5 mg/ml) were incubated at 25C in 0.22 M
mannitol, 71mMsucrose, 5mMHEPES/Tris buffer (pH 7.4), 5mMsuc-
cinate, 5 mM rotenone, and 3 mMoligomycin. Swelling was triggered by
the addition of complexes 1–4. Mitochondrial swelling was estimated
as absorbance decrease at 540 nmusing a Lambda-2 UV/VIS spectro-
photometer (Perkin-Elmer). To validate the experimental procedure,
mitochondrial swelling was triggered with 50 mM CaCl2 and 1 mM
Na,K-phosphate as positive control (not shown).
Determination of ROS Formation by Isolated
Rat Liver Mitochondria
Rat liver mitochondria (1 mg/ml) were incubated at 30C in 0.1 M su-
crose, 50 mM KCl, 0.5 mM Na,K-phosphate, 20 mM HEPES/Tris-
HCl buffer (pH 7.4). Hydrogen peroxide formed by exposure of isolated
mitochondria to complexes 1–4 was determined using the fluorogenic
probe Amplex Red (10 mM) in the presence of HRP (0.1 unit/ml) accord-
ing to Mohanty et al. [59]. Fluorescence was followed in a Cary Eclipse
Varian spectrofluorometer at 544 nm (excitation wavelength) and
620 nm (emission wavelength).Chemistry & Biology 14, 1128–113Determination of ROS Accumulation in HeLa Cells
Cells were seeded into Lab-Tek Chambered Glasses, 11 3 22 mm
4-well plates at a density of 53 104 cells per well. After 24 h of incuba-
tion, cells were loaded with the oxidation-sensitive probe DHR-123
(5 mM) for 30min, and then exposed to complexes 1–4 for an additional
30 min, in the presence or absence of the antioxidants Trolox or NAC.
At the end of treatment, cells were examined for ROS generation using
a Zeiss LSM-510 confocal laser microscope equipped with a CO2- and
temperature-controlled chamber.
Purification of Thioredoxin Reductase and Estimation of
Thioredoxin Reductase and Glutathione Reductase Activities
Cytosolic thioredoxin reductase (TrxR1) was prepared from rat liver ac-
cording to Luthman et al. [60]. Mitochondrial thioredoxin reductase
(TrxR2) was prepared from rat liver mitochondria according to Rigo-
bello et al. [61]. E. coli thioredoxin reductase was prepared according
to Williams et al. [62], whereas yeast glutathione reductase was used
as purchased (Sigma). The protein content of isolated enzymes was
estimated according to Lowry et al. [63]. Thioredoxin reductase activity
was measured at 25C in 0.2 M Na,K-Pi buffer (pH 7.5), 2 mM EDTA,
and 0.25 mM NADPH and started by the addition of 2 mM DTNB
and followed spectrophotometrically at 412 nm.Glutathione reductase
activity was assayed at 25C in 0.1 M Tris-HCl (pH 8.1) and 0.2 mM
NADPH. Reactions were initiated by 1 mM GSSG and followed spec-
trophotometrically at 340 nm. In both thioredoxin and glutathione re-
ductase assays the various gold(III) complexes were added after 5
min of incubation and, after 5 additional minutes, the reactions were
initiated by DTNB and GSSG, respectively.
Statistical Analyses
All the values are given as means ± SE of not less than three measure-
ments (unless otherwise stated). Multiple comparisons were made by
one-way analysis of variance followed by the Tukey-Kramer multiple
comparison test.
Supplemental Data
The Supplemental Data include details of the intermolecular interac-
tions and disorder in the X-ray structure of complex 4 and X-ray crys-
tallographic data in CIF format and can be found at http://www.
chembiol.com/cgi/content/full/14/10/1128/DC1/.
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